You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Risk factors for vancomycin‐associated acute kidney injury: A systematic review and meta‐analysis
Contributor:
Kim, Jee Yun;
Yee, Jeong;
Yoon, Ha Young;
Han, Ji Min;
Gwak, Hye Sun
Published:
Wiley, 2022
Published in:
British Journal of Clinical Pharmacology, 88 (2022) 9, Seite 3977-3989
Language:
English
DOI:
10.1111/bcp.15429
ISSN:
0306-5251;
1365-2125
Origination:
Footnote:
Description:
AimsThis systematic literature review and meta‐analysis aimed to evaluate the risk factors for vancomycin‐associated acute kidney injury (AKI) incidence.MethodsThis study assessed risk factors for vancomycin‐associated AKI in adult patients by searching studies from PubMed, the Cochrane Library and Embase. Random effect models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs).ResultsFifty‐three studies were included in our meta‐analysis. For patient factors, black race (OR 1.47, 95% CI: 1.16–1.87), Caucasian (OR 0.72, 95% CI: 0.58–0.90) and obesity (OR 1.46, 95% CI: 1.12–1.90) were associated with an increase in vancomycin‐associated AKIs. In terms of vancomycin‐related factors, longer treatment duration (>14 d; OR 1.73, 95% CI: 1.06–2.83), serum vancomycin trough level >15 μg/mL (OR 2.10, 95% CI: 1.43–3.07) and vancomycin trough level >20 μg/mL (OR 2.84, 95% CI: 1.48–5.44) increased the risks of vancomycin‐associated AKI. For comorbidities and clinical factors, renal disease (OR 2.19, 95% CI: 1.51–3.17) showed the highest odds of vancomycin‐associated AKI, followed by hepatic disease, intensive care unit admission, heart failure, sepsis, coronary heart disease and diabetes mellitus. For concomitant nephrotoxic drugs, amphotericin B (OR 5.21, 95% CI: 3.44–7.87) showed the highest odds of vancomycin‐associated AKI, followed by acyclovir (OR 3.22, 95% CI: 1.39–7.46), vasopressors, loop diuretics, piperacillin–tazobactam and aminoglycoside. The use of any concomitant nephrotoxic agent (OR 1.74, 95% CI: 1.17–2.58) increased the odds of vancomycin‐associated AKI.ConclusionOur results may help predict the risk of vancomycin‐associated AKI in the clinical setting.